Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Palvella Therapeutics reported Q1 2026 financial results, ending the period with $261.9 million in cash and investments following a $230 million equity financing completed in February. The company announced significant clinical progress, including a granted FDA Pre-NDA meeting for its lead asset QTORIN rapamycin for microcystic lymphatic malformations, with the meeting expected in Q2 2026 and NDA submission on track for H2 2026.
Key figures
- Revenue
- 0
- Drug Name
- QTORIN™ rapamycin
- Guidance
- NDA submission for QTORIN rapamycin in microcystic lymphatic malformations on track for second half of 2026; potential U.S. commercial launch in first half of 2027
- Revenue Yoy
- 0
- Deal Value Usd
- 230000000
- Phase Of Trial
- Phase 3
- Offering Price
- 0
- Shares Offered
- 0
- Net loss
- 15767000
- Ga expenses
- 5521000
- Rd expenses
- 9334000
- Shares outstanding
- 15738543
- Cash and investments
- 261900000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.